Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

CsA

Phase 3Small molecule

ZZhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd.

CsA is one of 96 small molecule programs targeting Aplastic Anemia. It is currently in Phase 3.

3

Indications

9

Total Trials

1

Active Trials

95

Competitors

Pipeline

Status by Indication[3][1]

Indication

Aplastic AnemiaActive, not recruiting

Eye DiseaseActive, not recruiting

Severe Aplastic AnemiaActive, not recruiting

Aplastic AnemiaPhase 2

Active, not recruiting

Eye DiseasePhase 3

Active, not recruiting

Severe Aplastic AnemiaPhase 2

Active, not recruiting

Competition

Competitive Landscape

200 competitors in Eye Disease

#DrugCompanyPhaseTrials

Neoral

Bayer Aspirin

Zovirax

BBp Consulting, Inc

Aquasol E

NNational Eye Institute (NEI)

CF101

CCan-Fite BioPharma

Carboxymethylcellulose

Refresh Plus

CsA

ZZhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd.

REFRESH LIQUIGEL

Refresh Optive

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Severe Aplastic Anemia3 trials

ATG Combined With Cyclophosphamide And Cord Blood Transfusion in Treating Patients With Severe Aplastic Anemia

Unknown status·JJinan Military General Hospital·Phase 4·NCT02838992·130 enrolled

A Phase II Dose-escalation Study Characterizing the PK of Eltrombopag in Pediatric Patients With Previously Untreated or Relapsed Severe Aplastic Anemia or Recurrent Aplastic Anemia

Completed· Novartis logo

Novartis·Phase 2·NCT03025698·51 enrolled

Rabbit Antithymocyte Globulin Versus Campath-1H for Treating Severe Aplastic Anemia

Completed·NNational Heart, Lung, and Blood Institute (NHLBI)·Phase 2·NCT00065260·54 enrolled

Efficacy and Safety2 trials

Efficacy and Safety Study of ATG for Prophylaxis of aGVHD in Matched Sibling Donor PBSCT

Completed·—·Phase 4·NCT02677181·100 enrolled

A Study to Evaluate the Efficacy and Safety of Treatment With CsA-PG Ophthalmic Gel in Dry Eye Patients

Not yet recruiting·ZZhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd.·Phase 3·NCT06942793·396 enrolled

Prophylaxis1 trial

ATG in HLA-matched Sibling HSCT as GVHD Prophylaxis

Unknown status·NNanfang Hospital, Southern Medical University·Phase 4·NCT04203108·266 enrolled

Eye Disease1 trial

Assess the Safety and Efficacy of CsA Ophthalmic Gel in Subjects With Moderate to Severe Dry Eye Disease

Completed·ZZhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd.·Phase 3·NCT04541888·644 enrolled

Aplastic Anemia1 trial

Eltrombopag in Combination With Rabbit Anti-thymocyte Globulin/Cyclosporine A in Naive Aplastic Anemia (AA) Subjects

Completed· Novartis logo

Novartis·Phase 2·NCT02404025·10 enrolled

1 more indication

Unspecified1 trial

hATG+CsA vs hATG+CsA+Eltrombopag for SAA

Completed·EEuropean Society for Blood and Marrow Transplantation·Phase 3·NCT02099747·202 enrolled

Sources

References

[1]
ClinicalTrials.gov — 9 trial records for CsA. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — CsA compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for CsA. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: ZZhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd.

Related News